Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB8939 in relapsed/refractory acute myeloid leukemia
NCT05211570Phase 2Recruiting
- Sponsor
- AB Science
- Start
- Jun 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of AB-8939 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by AB Science. Primary endpoint: Dose Limiting Toxicity at 56 days. Started Jun 2022; status: recruiting.
02
Drugs
AB-8939
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05211570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211570.